NRG
EW icon

Nemes Rush Group’s Edwards Lifesciences EW Stock Holding History

Nemes Rush Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3K Buy
236
+140
+146% +$11.7K ﹤0.01% 481
2026
Q1 		$7.69K Sell
96
-9
-9% -$742 ﹤0.01% 577
2025
Q4 		$8.95K Buy
105
+9
+9% +$739 ﹤0.01% 562
2025
Q3 		$7.47K Sell
96
-6
-6% -$469 ﹤0.01% 515
2025
Q2 		$7.98K Buy
102
+6
+6% +$447 ﹤0.01% 499
2025
Q1 		$6.96K Sell
96
-179
-65% -$12.8K ﹤0.01% 504
2024
Q4 		$20.4K Sell
275
-8,924
-97% -$625K ﹤0.01% 393
2024
Q3 		$879K Sell
9,199
-1,770
-16% -$129K 0.13% 91
2024
Q2 		$1.01M Buy
10,969
+1,651
+18% +$146K 0.14% 85
2024
Q1 		$890K Sell
9,318
-45,919
-83% -$3.86M 0.13% 92
2023
Q4 		$4.21M Buy
55,237
+2,995
+6% +$208K 0.68% 44
2023
Q3 		$3.62M Buy
52,242
+4,301
+9% +$346K 0.66% 45
2023
Q2 		$4.52M Buy
+47,941
New +$4.17M 0.8% 42

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Nemes Rush Group's EW Position: Q2 2026 in Review

Nemes Rush Group increased its Edwards Lifesciences (EW) stake by 146% in Q2 2026, buying an estimated $11.7K and bringing the position to 236 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #481.

Nemes Rush Group first reported a position in EW in Q2 2023 and has held it in 13 quarters since. The position peaked at $4.52M in Q2 2023. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Nemes Rush Group held 236 shares of Edwards Lifesciences worth $21.3K as of Q2 2026.
  • Nemes Rush Group bought 140 Edwards Lifesciences shares in Q2 2026, an estimated $11.7K.
  • Edwards Lifesciences made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #481 holding.
  • Nemes Rush Group first reported a position in Edwards Lifesciences in Q2 2023 and has held it in 13 quarters since.
  • Nemes Rush Group's Edwards Lifesciences position peaked at $4.52M in Q2 2023.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.